Cannabinoid effects on CB1 receptor density in the adolescent brain: An autoradiographic study using the synthetic cannabinoid HU210

Synapse

Volumn 64, Issue 11, 2010, Pages 845-854

  Dalton, Victoria S ^a,b   Zavitsanou, Katerina ^a,b  

^a SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

^b AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION   (Australia)

Author keywords

3H ; Adolescence; Adult; Autoradiography; CP55,940; Neuroadaptation; Rat

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; CANNABINOID RECEPTOR; DEXANABINOL;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BEHAVIOR; BODY WEIGHT; BRAIN; BRAIN REGION; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG BINDING; DRUG CROSS TOLERANCE; DRUG EFFECT; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR DENSITY; SINGLE DRUG DOSE; WEIGHT GAIN;

AGE FACTORS; ANALGESICS; ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; BODY WEIGHT; BRAIN; BRAIN MAPPING; CANNABINOIDS; CYCLOHEXANOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; PROTEIN BINDING; RADIOLIGAND ASSAY; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; TETRAHYDROCANNABINOL; TISSUE DISTRIBUTION; TRITIUM;

EID: 77953806698     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20801     Document Type: Article

References (58)

1. Andersen SL. 2003. Trajectories of brain development: Point of vulnerability or window of opportunity? Neurosci Biobehav Rev 27: 3-18.
2. Biscaia M, Fernández B, Higuera-Matas A, Miguéns M, Viveros M-P, García-Lecumberri C, Ambrosio E. 2008. Sex-dependent effects of periadolescent exposure to the cannabinoid agonist CP-55, 940 on morphine self-administration behaviour and the endogenous opioid system. Neuropharmacology 54: 863-873.
3. Breivogel CS, Childers SR. 1998. The functional neuroanatomy of brain cannabinoid receptors. Neurobiol Dis 5(Part B): 417-431.
4. Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Vogt LJ, Sim-Selley LJ. 1999. Chronic delta9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain. J Neurochem 73: 2447-2459.
5. Chambers RA, Taylor JR, Potenza MN. 2003. Developmental neurocircuitry of motivation in adolescence: A critical period of addiction vulnerability. Am J Psychiatry 160: 1041-1052.
6. Craig AA, Wiley JL, Burston JJ, Selley DE, Sim-Selly LJ. 2007. Effects of repeated administration of Δ9-THC on cannabinoid CB1 receptor density and function in adolescent and adult rats. 17th Annual Symposium on the Cannabinoids, Burlington, Vermont, International Cannabinoid Research Society, p 82.
7. Dalton VS, Wang H, Zavitsanou K. 2009. HU210-induced downregulation in cannabinoid CB1 receptor binding strongly correlates with body weight loss in the adult rat. Neurochem Res 34: 1343-1353.
8. Ehrenreich H, Rinn T, Kunert HJ, Moeller MR, Poser W, Schilling L, Gigerenzer G, Hoehe MR. 1999. Specific attentional dysfunction in adults following early start of cannabis use. Psychopharmacology (Berl) 142: 295-301.
9. Ellgren M, Spano SM, Hurd YL. 2007. Adolescent cannabis exposure alters opiate intake and opioid limbic neuronal populations in adult rats. Neuropsychopharmacology 32: 607-615.
10. Fox KM, Sterling RC, Van Bockstaele EJ. 2009. Cannabinoids and novelty investigation: Influence of age and duration of exposure. Behav Brain Res 196: 248-253.
11. Fride E, Bregman T, Kirkham TC. 2005. Endocannabinoids and food intake: Newborn suckling and appetite regulation in adulthood. Exp Biol Med (Maywood) 230: 225-234.
12. Giuliani D, Ottani A, Ferrari F. 2000. Effects of the cannabinoid receptor agonist. HU 210, on ingestive behaviour and body weight of rats. Eur J Pharmacol 391: 275-279.
13. González S, Cebeira M, Fernández-Ruiz J. 2005. Cannabinoid tolerance and dependence: A review of studies in laboratory animals. Pharmacol Biochem Behav 81: 300-318.
14. Izenwasser S. 2005. Differential effects of psychoactive drugs in adolescents and adults. Crit Rev Neurobiol 17: 51-67.
15. Kota BP, Huang TH-W, Roufogalis BD. 2005. An overview on biological mechanisms of PPARs. Pharmacol Res 51: 85-94.
16. Lamota L, Bermudez-Silva FJ, Marco E-M, Llorente R, Gallego A, Rodríguez de Fonseca F, Viveros M-P. 2008. Effects of adolescent nicotine and SR 147778 (Surinabant) administration on food intake, somatic growth and metabolic parameters in rats. Neuropharmacology 54: 194-205.
17. Ledent C, Valverde O, Cossu G, Petitet F, Aubert J-F, Beslot F, Böhme GA, Imperato A, Pedrazzini T, Roques BP, Vassart G, Fratta W, Parmentier M. 1999. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283: 401-404.
18. Lohse MJ. 1993. Molecular mechanisms of membrane receptor desensitization. Biochim Biophys Acta 1179: 171-188.
19. Luzi S, Morrison PD, Powell J, di Forti M, Murray RM. 2008. What is the mechanism whereby cannabis use increases risk of psychosis? Neurotox Res 14(2-3): 105-112.
20. Mechoulam R, Feigenbaum JJ, Lander N, Segal M, Järbe TUC, Hiltunen AJ, Consroe P. 1988. Enantiomeric cannabinoids: Stereospecificity of psychotropic activity. Experientia 44: 762-764.
21. Monory K, Blaudzun H, Massa F, Kaiser N, Lemberger T, Schütz G, Wotjak CT, Lutz B, Marsicano G. 2007. Genetic dissection of behavioural and autonomic effects of Delta(9)-tetrahydrocannabinol in mice. PLoS Biol 5: e269.
22. O'Shea M, Singh ME, McGregor IS, Mallet PE. 2004. Chronic cannabinoid exposure produces lasting memory impairment and increased anxiety in adolescent but not adult rats. J Psychopharmacol 18: 502-508.
23. O'Sullivan SE. 2007. Cannabinoids go nuclear: Evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol 152: 576-582.
24. Ottani A, Giuliani D. 2001. Hu 210: A potent tool for investigations of the cannabinoid system. CNS Drug Rev 7: 131-145.
25. Oviedo A, Glowa J, Herkenham M. 1993. Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: A quantitative autoradiographic study. Brain Res 616(1-2): 293-3023.
26. Paxinos G, Watson C. 2007. The rat brain in stereotaxic coordinates. Sydney: Academic Press.
27. Pandolfo P, Pamplona FA, Prediger RDS, Takahashi RN. 2007. Increased sensitivity of adolescent spontaneously hypertensive rats, an animal model of attention deficit hyperactivity disorder, to the locomotor stimulation induced by the cannabinoid receptor agonist WIN 55, 212-2. Eur J Pharmacol 563(1-3): 141-148.
28. Pattij T, Wiskerke J, Schoffelmeer AN. 2008. Cannabinoid modulation of executive functions. Eur J Pharmacol 585(2-3): 458-463.
29. Pistis M, Perra S, Pillolla G, Melis M, Muntoni AL, Gessa GL. 2004. Adolescent exposure to cannabinoids induces long-lasting changes in the response to drugs of abuse of rat midbrain dopamine neurons. Biol Psychiatry 56: 86-94.
30. Quinn HR, Matsumoto I, Callaghan PD, Long LE, Arnold JC, Gunasekaran N, Thompson MR, Dawson B, Mallet PE, Kashem MA, Matsuda-Matsumoto H, Iwazaki T, McGregor IS. 2008. Adolescent rats find repeated delta(9)-THC less aversive than adult rats but display greater residual cognitive deficits and changes in hippocampal protein expression following exposure. Neuropsychopharmacology 33: 1113-1126.
31. Realini N, Rubino T, Parolaro D. 2009. Neurobiological alterations at adult age triggered by adolescent exposure to cannabinoids. Pharmacol Res 60: 132-138.
32. Rodríguez de Fonseca F, Ramos JA, Bonnin A, Fernández-Ruiz JJ. 1993. Presence of cannabinoid binding sites in the brain from early postnatal ages. Neuroreport 4: 135-138.
33. Romero J, Garcia-Palomero E, Castro JG, Garcia-Gil L, Ramos JA, Fernández -Ruiz JJ. 1997. Effects of chronic exposure to delta9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions. Brain Res Mol Brain Res 46(1-2): 100-108.
34. Romero J, Berrendero F, Manzanares J, Pérez A, Corchero J, Fuentes JA, Fernández -Ruiz JJ, Ramos JA. 1998. Time-course of the cannabinoid receptor down-regulation in the adult rat brain caused by repeated exposure to delta9-tetrahydrocannabinol. Synapse 30: 298-308.
35. Romero J, Lastres-Becker I, de Miguel R, Berrendero F, Ramos JA, Fernández-Ruiz J. 2002a. The endogenous cannabinoid system and the basal ganglia. Biochemical, pharmacological, and therapeutic aspects. Pharmacol Ther 95: 137-152.
36. Romero EM, Fernández B, Sagredo O, Gomez N, Urigüen L, Guaza C, De Miguel R, Ramos JA, Viveros MP. 2002b. Antinociceptive, behavioural and neuroendocrine effects of CP 55, 940 in young rats. Brain Res Dev Brain Res 136: 85-92.
37. Rubino T, Parolaro D. 2008. Long lasting consequences of cannabis exposure in adolescence. Mol Cell Endocrinol 286(1-2 Suppl 1 ): S108-S113.
38. Rubino T, Viganò D, Realini N, Guidali C, Braida D, Capurro V, Castiglioni C, Cherubino F, Romualdi P, Candeletti S, Sala M, Parolaro D. 2008. Chronic delta(9)-tetrahydrocannabinol during adolescence provokes sex-dependent changes in the emotional profile in adult rats: Behavioral and biochemical correlates. Neuropsychopharmacology 33: 2760-2771.
39. Rubino T, Realini N, Braida D, Guidi S, Capurro V, Viganò D, Guidali C, Pinter M, Sala M, Bartesaghi R, Parolaro D. 2009. Changes in hippocampal morphology and neuroplasticity induced by adolescent THC treatment are associated with cognitive impairment in adulthood. Hippocampus 19: 763-772.
40. Schneider M. 2008. Puberty as a highly vulnerable developmental period for the consequences of cannabis exposure. Addict Biol 13: 253-263.
41. Schneider M, Koch M. 2003. Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology 28: 1760-1769.
42. Schneider M, Schömig E, Leweke FM. 2008. Acute and chronic cannabinoid treatment differentially affects recognition memory and social behavior in pubertal and adult rats. Addict Biol 13(3-4): 345-357.
43. Schramm-Sapyta NL, Cha YM, Chaudhry S, Wilson WA, Swartzwelder HS, Kuhn CM. 2007. Differential anxiogenic, aversive, and locomotor effects of THC in adolescent and adult rats. Psychopharmacology (Berl) 191: 867-877.
44. Sébert SP, Lecannu G, Kozlowski F, Siliart B, Bard JM, Krempf M, Champ MM-J. 2005. Childhood obesity and insulin resistance in a Yucatan mini-piglet model: Putative roles of IGF-1 and muscle PPARs in adipose tissue activity and development. Int J Obes (Lond) 29: 324-333.
45. Sigel E. 2008. Eating disorders. Adolesc Med State Art Rev 19: 547-572.
46. Sim-Selley LJ. 2003. Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Crit Rev Neurobiol 15: 91-119.
47. Sim-Selley LJ, Martin BR. 2002. Effect of chronic administration of R-(+)-[2, 3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1, 2, 3-de]-1, 4-b enzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55, 212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice. J Pharmacol Exp Ther 303: 36-44.
48. Spear LP. 2000. The adolescent brain and age-related behavioral manifestations. Neurosci Biobehav Rev 24: 417-463.
49. Spear LP, Brake SC. 1983. Periadolescence: Age-dependent behavior and psychopharmacological responsivity in rats. Dev Psychobiol 16: 83-109.
50. Trezza V, Cuomo V, Vanderschuren LJMJ. 2008. Cannabis and the developing brain: Insights from behavior. Eur J Pharmacol 585: 441-452.
51. van der Stelt M, Di Marzo V. 2003. The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: Implications for neurological and psychiatric disorders. Eur J Pharmacol 480(1-3): 133-150.
52. Verberne AJM, Taylor DA, Fennessy MR. 1980. Withdrawal-like behaviour induced by inhibitors of biogenic amine reuptake in rats treated chronically with delta 9-tetrahydrocannabinol. Psychopharmacology (Berl) 68: 261-267.
53. Viveros MP, Rodríguez de Fonseca F, Bermudez-Silva FJ, McPartland JM. 2008. Critical role of the endocannabinoid system in the regulation of food intake and energy metabolism, with phylogenetic, developmental, and pathophysiological implications. Endocr Metab Immune Disord Drug Targets 8: 220-230.
54. Wang T, Collet JP, Shapiro S, Ware MA. 2008. Adverse effects of medical cannabinoids: A systematic review. CMAJ 178: 1669-1678.
55. Wegener N, Koch M. 2009. Behavioural disturbances and altered Fos protein expression in adult rats after chronic pubertal cannabinoid treatment. Brain Res 1253: 81-91.
56. Wiley JL, O'Connell MM, Tokarz ME, Wright MJ, Jr. 2007. Pharmacological effects of acute and repeated administration of Delta(9)-tetrahydrocannabinol in adolescent and adult rats. J Pharmacol Exp Ther 320: 1097-1105.
57. Wilson RI, Nicoll RA. 2002. Endocannabinoid signaling in the brain. Science 296: 678-682.
58. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI. 1999. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci USA 96: 5780-5785.